ImmuCell (ICCC) vs. Its Peers Head-To-Head Review

ImmuCell (NASDAQ:ICCC) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare ImmuCell to similar companies based on the strength of its analyst recommendations, valuation, institutional ownership, profitability, earnings, dividends and risk.

Risk & Volatility

ImmuCell has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, ImmuCell’s rivals have a beta of -3.71, suggesting that their average share price is 471% less volatile than the S&P 500.

Institutional and Insider Ownership

13.5% of ImmuCell shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 5.7% of ImmuCell shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares ImmuCell and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ImmuCell	2.57%	2.69%	1.76%
ImmuCell Competitors	-2,380.38%	-217.94%	-15.54%

Analyst Recommendations

This is a summary of current recommendations and price targets for ImmuCell and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	0	1	0	0	2.00
ImmuCell Competitors	7798	13888	25778	1037	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 25.65%. Given ImmuCell’s rivals stronger consensus rating and higher probable upside, analysts plainly believe ImmuCell has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares ImmuCell and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ImmuCell	$27.64 million	-$1.04 million	122.50
ImmuCell Competitors	$3.54 billion	$3.18 billion	553.85

ImmuCell’s rivals have higher revenue and earnings than ImmuCell. ImmuCell is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

ImmuCell rivals beat ImmuCell on 9 of the 13 factors compared.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.